Potrero Hill Therapeutics
San Francisco, CA · Biotech · Private
Small molecule inhibitors of dihydroceramide desaturase-1 (DES1) for oral treatment of type 2 diabetes and metabolic diseases
potrerohilltherapeutics.com →- Grants
- $8.4M
- 8 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- —
- No published records under this name
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2017201820192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | $225,000 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Dihydroceramide Desaturase Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | $225,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | $749,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | $749,999 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase II · Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | $1,069,999 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase II · Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | $3,209,997 | |
| Federal grant | Department of Health and Human Services · Phase II · Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | $1,069,999 | |
| Federal grant | Department of Health and Human Services · Phase II · Dihydroceramide Desaturase-1 Inhibitors for Treatment of Diabetes and Other Metabolic Diseases | $1,069,999 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1538 | Glyco Expression Technologies (Corporation) | — | — |
| 1539 | Purilogics, LLC | — | — |
| 1540 | Biophytis SA | — | $4.2M |
| 1541 | Potrero Hill Therapeutics | — | — |
| 1542 | 3HELIX INC | — | $12M |
| 1543 | Adcytherix | — | — |
| 1544 | WALIA, RAMPYARI | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.